vs
Globe Life（GL）与瑞思迈（RMD）财务数据对比。点击上方公司名可切换其他公司
Globe Life的季度营收约是瑞思迈的1.1倍（$1.6B vs $1.4B），瑞思迈净利率更高（27.6% vs 17.3%，领先10.2%），瑞思迈同比增速更快（11.0% vs 5.3%），过去两年瑞思迈的营收复合增速更高（9.0% vs 4.1%）
Globe Life Inc.（股票代码：GL）是总部位于美国得克萨斯州麦金尼的金融服务控股公司，在纽约证券交易所上市，通过旗下全资子公司开展业务，主营人寿保险、年金产品及补充健康保险产品。
瑞思迈是一家起源于澳大利亚、总部位于美国加利福尼亚州圣迭戈的医疗设备企业，主打可接入云端的呼吸类医疗设备，用于治疗睡眠呼吸暂停、慢性阻塞性肺病等呼吸道疾病，新冠疫情期间曾大量生产呼吸机等设备助力患者救治。
GL vs RMD — 直观对比
营收规模更大
GL
是对方的1.1倍
$1.4B
营收增速更快
RMD
高出5.6%
5.3%
净利率更高
RMD
高出10.2%
17.3%
两年增速更快
RMD
近两年复合增速
4.1%
损益表 — Q1 FY2026 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.6B | $1.4B |
| 净利润 | $270.5M | $392.6M |
| 毛利率 | — | 61.8% |
| 营业利润率 | — | 34.6% |
| 净利率 | 17.3% | 27.6% |
| 营收同比 | 5.3% | 11.0% |
| 净利润同比 | 6.3% | 13.9% |
| 每股收益（稀释后） | $3.39 | $2.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GLRMD
| Q1 26 | $1.6B | — | ||
| Q4 25 | $1.5B | $1.4B | ||
| Q3 25 | $1.5B | $1.3B | ||
| Q2 25 | $1.5B | $1.3B | ||
| Q1 25 | $1.5B | $1.3B | ||
| Q4 24 | $1.5B | $1.3B | ||
| Q3 24 | $1.5B | $1.2B | ||
| Q2 24 | $1.4B | $1.2B |
净利润GLRMD
| Q1 26 | $270.5M | — | ||
| Q4 25 | $266.1M | $392.6M | ||
| Q3 25 | $387.8M | $348.5M | ||
| Q2 25 | $252.7M | $379.7M | ||
| Q1 25 | $254.6M | $365.0M | ||
| Q4 24 | $255.2M | $344.6M | ||
| Q3 24 | $303.0M | $311.4M | ||
| Q2 24 | $258.4M | $292.2M |
毛利率GLRMD
| Q1 26 | — | — | ||
| Q4 25 | — | 61.8% | ||
| Q3 25 | — | 61.5% | ||
| Q2 25 | — | 60.8% | ||
| Q1 25 | — | 59.3% | ||
| Q4 24 | — | 58.6% | ||
| Q3 24 | 26.1% | 58.6% | ||
| Q2 24 | 23.3% | 58.5% |
营业利润率GLRMD
| Q1 26 | — | — | ||
| Q4 25 | 21.7% | 34.6% | ||
| Q3 25 | 31.5% | 33.4% | ||
| Q2 25 | 21.2% | 33.7% | ||
| Q1 25 | 21.4% | 33.0% | ||
| Q4 24 | 21.3% | 32.5% | ||
| Q3 24 | 26.3% | 31.6% | ||
| Q2 24 | 23.5% | 31.2% |
净利率GLRMD
| Q1 26 | 17.3% | — | ||
| Q4 25 | 17.5% | 27.6% | ||
| Q3 25 | 25.6% | 26.1% | ||
| Q2 25 | 17.1% | 28.2% | ||
| Q1 25 | 17.2% | 28.3% | ||
| Q4 24 | 17.4% | 26.9% | ||
| Q3 24 | 20.8% | 25.4% | ||
| Q2 24 | 17.9% | 23.9% |
每股收益（稀释后）GLRMD
| Q1 26 | $3.39 | — | ||
| Q4 25 | $3.28 | $2.68 | ||
| Q3 25 | $4.73 | $2.37 | ||
| Q2 25 | $3.05 | $2.58 | ||
| Q1 25 | $3.01 | $2.48 | ||
| Q4 24 | $3.00 | $2.34 | ||
| Q3 24 | $3.44 | $2.11 | ||
| Q2 24 | $2.83 | $1.97 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $183.8M | $1.4B |
| 总债务越低越好 | — | $403.9M |
| 股东权益账面价值 | $6.1B | $6.3B |
| 总资产 | — | $8.5B |
| 负债/权益比越低杠杆越低 | — | 0.06× |
8季度趋势，按日历期对齐
现金及短期投资GLRMD
| Q1 26 | $183.8M | — | ||
| Q4 25 | $314.7M | $1.4B | ||
| Q3 25 | $62.8M | $1.4B | ||
| Q2 25 | $116.7M | $1.2B | ||
| Q1 25 | $134.1M | $932.7M | ||
| Q4 24 | $85.0M | $521.9M | ||
| Q3 24 | $100.5M | $426.4M | ||
| Q2 24 | $100.6M | $238.4M |
总债务GLRMD
| Q1 26 | — | — | ||
| Q4 25 | — | $403.9M | ||
| Q3 25 | — | $408.7M | ||
| Q2 25 | — | $658.4M | ||
| Q1 25 | — | $663.1M | ||
| Q4 24 | — | $662.9M | ||
| Q3 24 | — | $667.6M | ||
| Q2 24 | — | $697.3M |
股东权益GLRMD
| Q1 26 | $6.1B | — | ||
| Q4 25 | $6.0B | $6.3B | ||
| Q3 25 | $5.7B | $6.1B | ||
| Q2 25 | $5.4B | $6.0B | ||
| Q1 25 | $5.4B | $5.5B | ||
| Q4 24 | $5.3B | $5.3B | ||
| Q3 24 | $4.6B | $5.2B | ||
| Q2 24 | $5.2B | $4.9B |
总资产GLRMD
| Q1 26 | — | — | ||
| Q4 25 | $30.8B | $8.5B | ||
| Q3 25 | $30.5B | $8.3B | ||
| Q2 25 | $29.8B | $8.2B | ||
| Q1 25 | $29.7B | $7.6B | ||
| Q4 24 | $29.1B | $7.1B | ||
| Q3 24 | $29.6B | $7.2B | ||
| Q2 24 | $28.3B | $6.9B |
负债/权益比GLRMD
| Q1 26 | — | — | ||
| Q4 25 | — | 0.06× | ||
| Q3 25 | — | 0.07× | ||
| Q2 25 | — | 0.11× | ||
| Q1 25 | — | 0.12× | ||
| Q4 24 | — | 0.13× | ||
| Q3 24 | — | 0.13× | ||
| Q2 24 | — | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $339.7M |
| 自由现金流经营现金流 - 资本支出 | — | $311.2M |
| 自由现金流率自由现金流/营收 | — | 21.9% |
| 资本支出强度资本支出/营收 | — | 2.0% |
| 现金转化率经营现金流/净利润 | — | 0.87× |
| 过去12个月自由现金流最近4个季度 | — | $1.8B |
8季度趋势，按日历期对齐
经营现金流GLRMD
| Q1 26 | — | — | ||
| Q4 25 | $350.6M | $339.7M | ||
| Q3 25 | $306.0M | $457.3M | ||
| Q2 25 | $307.9M | $538.8M | ||
| Q1 25 | $431.9M | $578.7M | ||
| Q4 24 | $336.9M | $308.6M | ||
| Q3 24 | $340.6M | $325.5M | ||
| Q2 24 | $374.1M | $440.1M |
自由现金流GLRMD
| Q1 26 | — | — | ||
| Q4 25 | $330.1M | $311.2M | ||
| Q3 25 | $208.7M | $414.4M | ||
| Q2 25 | $295.0M | $508.2M | ||
| Q1 25 | $420.1M | $557.9M | ||
| Q4 24 | $321.9M | $288.0M | ||
| Q3 24 | $311.3M | $307.7M | ||
| Q2 24 | $356.5M | $415.2M |
自由现金流率GLRMD
| Q1 26 | — | — | ||
| Q4 25 | 21.7% | 21.9% | ||
| Q3 25 | 13.8% | 31.0% | ||
| Q2 25 | 19.9% | 37.7% | ||
| Q1 25 | 28.4% | 43.2% | ||
| Q4 24 | 22.0% | 22.5% | ||
| Q3 24 | 21.4% | 25.1% | ||
| Q2 24 | 24.8% | 33.9% |
资本支出强度GLRMD
| Q1 26 | — | — | ||
| Q4 25 | 1.3% | 2.0% | ||
| Q3 25 | 6.4% | 3.2% | ||
| Q2 25 | 0.9% | 2.3% | ||
| Q1 25 | 0.8% | 1.6% | ||
| Q4 24 | 1.0% | 1.6% | ||
| Q3 24 | 2.0% | 1.5% | ||
| Q2 24 | 1.2% | 2.0% |
现金转化率GLRMD
| Q1 26 | — | — | ||
| Q4 25 | 1.32× | 0.87× | ||
| Q3 25 | 0.79× | 1.31× | ||
| Q2 25 | 1.22× | 1.42× | ||
| Q1 25 | 1.70× | 1.59× | ||
| Q4 24 | 1.32× | 0.90× | ||
| Q3 24 | 1.12× | 1.05× | ||
| Q2 24 | 1.45× | 1.51× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GL
| Life premium | $853.2M | 55% |
| Health premium | $416.9M | 27% |
| Other | $289.5M | 19% |
RMD
| Sleep And Breathing Health | $1.3B | 88% |
| Residential Care Software | $166.9M | 12% |
